RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$40.21-5.65%
Price as of Jul 20, 2026
RAPP growth
Rapport Therapeutics, Inc. Common Stock growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -28.2%
- EBIT
- -31.3%
- EPS
- —
- Free cash flow
- -16.8%
- Operating cash flow
- -19.0%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -41.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -60.2%
- EBIT
- -50.6%
- Net income
- -42.4%
- EPS
- +24.3%
- Free cash flow
- -31.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.